BOTAl was established in 2018, with its headquarters in Ningbo City, China, and is a high-tech enterprise with immunodiagnostic technology as the core and- integrating R&D, production and sales.
Relying on the biological raw material technology platform independently developed and produced by antigen and antibody, as well as mature ELISA platform,GICT platform,IFA platform and CLIA platform,BOTAI has developed and formed POCT reagents in seven major fields covering infectious disease detection, vector-borned disease detection, respiratory disease detection inflammation detection, tumor detection, zoonotic disease detectionand animal(pet/economic animal) disease screening, and has now formed the depth of the industrial chain from upstream core raw materials to diagnostic reagents.Serving more than 150 countries and regions around the world.